Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy and safety of tigecycline with those of levofloxacin in the treatment
of subjects with CAP requiring hospitalization. The co-primary efficacy endpoints in the
study will be the clinical response in the clinically evaluable population and the clinical
response in the clinical modified intent-to-treat population at the TOC visit. The primary
efficacy analyses will first determine whether tigecycline is noninferior to levofloxacin. If
tigecycline is found to be noninferior, the analyses will determine whether tigecycline is
statistically better than levofloxacin.